News News – 2021 Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies Continue Reading
News News – 2021 Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board Continue Reading
News News – 2021 Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting Continue Reading
News News – 2021 Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer Continue Reading
News News – 2021 Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers Continue Reading
News News – 2021 Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors Continue Reading
News News – 2021 Hummingbird Bioscience Strengthens Leadership Team with Appointment of Josh House as Chief Financial Officer Continue Reading
News News – 2021 Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers Continue Reading
News News – 2021 Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors Continue Reading
